injection in children in New Zealand, 1985-1988. Submitted to the Vaccine Safety Committee, Institute of Medicine, Washington, DC, May 4, 1992.
National Center for Health Statistics. Current Estimates from the National Health Interview Survey, United States, 1988. Vital and Health Statistics, Series 10, No. 173. Washington, DC: U.S. Government Printing Office; 1989.
Ng PL, Powell LW, Campbell CP. Guillain-Barré syndrome during the preicteric phase of acute type B viral hepatitis. Australia and New Zealand Journal of Medicine 1975;5:367.
Niermeijer P, Gips CH. Guillain-Barré syndrome in acute HBS Ag-positive hepatitis. British Medical Journal 1975;4:732.
Penner E, Maida E, Mamoli B, Gangl A. Serum and cerebrospinal fluid immune complexes containing hepatitis B surface antigen in Guillain-Barré syndrome. Gastroenterology 1982;82:576-580.
Purcell RH, Gerin JL. Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. American Journal of Medical Science 1975;270:395-399.
Ribera EF, Dutka AJ. Polyneuropathy associated with administration of hepatitis B vaccine (letter). New England Journal of Medicine 1983;309:614-615.
Rogerson SJ, Nye FJ. Hepatitis B vaccine associated with erythema nodosum and polyarthritis. British Medical Journal 1990;301:345.
Schumacher HR, Gall EP. Arthritis in acute hepatitis and chronic active hepatitis: pathology of the synovial membranes with evidence of Australian antigen in synovial membranes. American Journal of Medicine 1974;57:655-664.
Shaw FE Jr, Graham DJ, Guess HA, Milstien JB, Johnson JM, Schatz GC, et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination: experience of the first three years . American Journal of Epidemiology 1988;127:337-352.
Shaw FE, Guess HA, Roets JM. The effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989;7:425-430.
Stephenne J. Development and production aspects of a recombinant yeast derived hepatitis vaccine. Vaccine 1990:8(Suppl.):S69-S73.
Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. New England Journal of Medicine 1980;303:833-841.
Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross protection. New England Journal of Medicine 1982;307:1481-1486.
Tabor E. Guillain-Barré syndrome and other neurologic syndromes in hepatitis A, B, and non-A, non-B. Journal of Medical Virology 1987;21:207-216.
Tsukada N, Koh CS, Inoue A, Yanigasawa N. Demyelinating neuropathy associated with hepatitis B virus infection . Journal of Neurological Science 1987;77:203-216.
Tuohy PG. Guillain-Barré syndrome following immunization with synthetic hepatitis B vaccine (letter). New Zealand Medical Journal 1989;102:114-115.
Waisbren BA. A commentary, regarding personal observations of demyelinizing disease caused by viral vaccines, borrelia infections, and proteolytic enzymes. Paper submitted to the Vaccine Safety Committee, Institute of Medicine, Washington, DC, August 11, 1992.
Wake RAE, White MI. Erythema multiforme associated with hepatitis B vaccine (letter). British Journal of Dermatology 1992;126:94-95.
Wands JR, Mann E, Alpert E. The pathogenesis of arthritis associated with acute hepatitis B surface antigen-positive hepatitis: complement activation and characterization of circulating immune complexes. Journal of Clinical Investigation 1975;55:930-939.
West DH, Calandra GB, Ellis RW. Vaccination of infants and children against hepatitis B. Pediatric Clinics of North America 1990;37:585-601.